最近通过FDA或EMA评估的口服抗covid -19药物:综述

Dorota Lorenz, R. Pawliczak
{"title":"最近通过FDA或EMA评估的口服抗covid -19药物:综述","authors":"Dorota Lorenz, R. Pawliczak","doi":"10.5114/pja.2022.114394","DOIUrl":null,"url":null,"abstract":"Y COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time passed it became clear that, aside from the vaccines, other efficient methods of fighting the disease are urgently needed. Among the whole list of medicines used to treat COVID-19, those which are administered orally have a great advantage. The aim of this paper is to present the current knowledge about the recently investigated oral medications for COVID-19. The authors present molnupiravir (Lagevrio), baricitinib (Olumiant) and ritonavir + PF-07321332 (Paxlovid). All of these drugs have been registered recently or are waiting for authorization by EMA or FDA. During the study, the authors learned that huge progress was made, nevertheless, more studies are needed, especially in the field of side effects and drug-drug interactions of the considered substances.","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review\",\"authors\":\"Dorota Lorenz, R. Pawliczak\",\"doi\":\"10.5114/pja.2022.114394\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Y COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time passed it became clear that, aside from the vaccines, other efficient methods of fighting the disease are urgently needed. Among the whole list of medicines used to treat COVID-19, those which are administered orally have a great advantage. The aim of this paper is to present the current knowledge about the recently investigated oral medications for COVID-19. The authors present molnupiravir (Lagevrio), baricitinib (Olumiant) and ritonavir + PF-07321332 (Paxlovid). All of these drugs have been registered recently or are waiting for authorization by EMA or FDA. During the study, the authors learned that huge progress was made, nevertheless, more studies are needed, especially in the field of side effects and drug-drug interactions of the considered substances.\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pja.2022.114394\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pja.2022.114394","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 2

摘要

新冠肺炎是一种由冠状病毒SARS-CoV-2引起的传染病。随着时间的推移,很明显,除了疫苗之外,迫切需要其他有效的方法来对抗这种疾病。在用于治疗COVID-19的整个药物清单中,口服药物具有很大优势。本文的目的是介绍最近研究的COVID-19口服药物的最新知识。作者推荐莫努匹拉韦(Lagevrio)、巴比替尼(Olumiant)和利托那韦+ PF-07321332 (Paxlovid)。所有这些药物最近都已注册或正在等待EMA或FDA的授权。在研究过程中,作者了解到已经取得了巨大的进展,但还需要进行更多的研究,特别是在所考虑的物质的副作用和药物-药物相互作用领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Oral anti-COVID-19 drugs that were recently evaluated by FDA or EMA: a review
Y COVID-19 is an infectious disease that is caused by coronavirus SARS-CoV-2. As the time passed it became clear that, aside from the vaccines, other efficient methods of fighting the disease are urgently needed. Among the whole list of medicines used to treat COVID-19, those which are administered orally have a great advantage. The aim of this paper is to present the current knowledge about the recently investigated oral medications for COVID-19. The authors present molnupiravir (Lagevrio), baricitinib (Olumiant) and ritonavir + PF-07321332 (Paxlovid). All of these drugs have been registered recently or are waiting for authorization by EMA or FDA. During the study, the authors learned that huge progress was made, nevertheless, more studies are needed, especially in the field of side effects and drug-drug interactions of the considered substances.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
50.00%
发文量
18
期刊介绍: Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.
期刊最新文献
Significantly higher death toll along with COVID-19 mortality than influenza have been reduced by vaccination and restrictions Allergic contact dermatitis caused by diabetes medical devices Small airways dysfunction – unappreciated feature of asthma Safety of COVID-19 vaccination among patients with history of allergic reactions The effectiveness of new antibiotics in the treatment of community-acquired pneumonia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1